Skip to main
  1. Stocks
  2. LifeMD
  3. Forecast
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD is viewed positively because its direct-to-patient telehealth model lowers friction for consumers facing long wait times and provider shortages, while its integrated pharmacy, care center, and AI-enabled infrastructure create a scalable, one-stop healthcare platform. Growth is being reinforced by high-demand categories: about 108,000 weight management subscribers at end-2Q26, 356,000 active subscribers, 95% of new weight-management patients starting branded GLP-1s, and women’s health patient growth of 134% sequentially with a projected $3M-$5M quarterly revenue run rate in 4Q26. The AT&T collaboration could materially expand reach without added acquisition cost by tapping 29 million eligible customers initially and more than 100 million nationwide over time, while rising insurance coverage and early Medicare adoption add additional upside.

Bears say

LifeMD is facing a weaker fundamental setup because 2Q26 revenue of $47.3M fell 4% year over year and missed expectations, while adjusted EBITDA of ($3.5M) and a net loss of $7.9M showed profitability remains pressured. Management lowered FY2026 revenue guidance to $205.5M-$212.5M from $220M-$230M and adjusted EBITDA to ($6M)-break-even as higher customer acquisition costs, competitive discounting, and the costly transition to branded GLP-1s weighed on results. Although weight management subscribers reached about 108,000 and total active subscribers rose 20% year over year to about 356,000, only about 8,000 new weight loss members were added in 2Q26, suggesting growth is not yet offsetting the margin drag and execution risk.

LifeMD (LFMD) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

LifeMD (LFMD) Analyst Forecast & Price Prediction

Get the latest LifeMD (LFMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LifeMD (LFMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 6 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


LifeMD (LFMD) Analyst Forecast & Price Prediction

Get the latest LifeMD (LFMD) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LifeMD (LFMD)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LFMD stock data and trends